ALKERMES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.44 USD | -0.85% |
|
+2.86% | -11.90% |
| Apr. 09 | Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday | MT |
| Apr. 09 | Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study | MT |
Financials (USD)
| Sales 2024 * | 1.52B | Sales 2025 * | 1.52B | Capitalization | 4.17B |
|---|---|---|---|---|---|
| Net income 2024 * | 352M | Net income 2025 * | 331M | EV / Sales 2024 * | 2.23 x |
| Net cash position 2024 * | 791M | Net cash position 2025 * | 1.17B | EV / Sales 2025 * | 1.97 x |
| P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
13.3
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alkermes plc
More recommendations
More press releases
| 1 day | +1.57% | ||
| 1 week | +2.67% | ||
| Current month | -8.94% | ||
| 1 month | -9.67% | ||
| 3 months | -12.34% | ||
| 6 months | -2.65% | ||
| Current year | -11.14% |
1 week
23.48
24.81
1 month
23.4827.56
Current year
23.4832.88
1 year
22.0133.71
3 years
21.1733.71
5 years
11.9833.71
10 years
11.9880.71
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Blair Jackson
DFI | Director of Finance/CFO | 51 | 98-12-31 |
Shane Cooke
PSD | President | 61 | 11-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 16-05-25 |
Brian McKeon
BRD | Director/Board Member | 61 | 20-12-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.32% | 215 M€ | +11.68% | - | |
| 2.65% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 24.44 | -0.85% | 1 313 171 |
| 24-04-24 | 24.65 | +1.61% | 1,737,019 |
| 24-04-23 | 24.26 | +0.79% | 1,245,764 |
| 24-04-22 | 24.07 | +0.92% | 1,708,265 |
| 24-04-19 | 23.85 | +0.38% | 2,414,813 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
24.65
USD
Average target price
35.25
USD
Spread / Average Target
+43.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.14% | 4.17B | |
| +4.09% | 43.84B | |
| +47.07% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- ALKS Stock
